Renuka Sothinathan, MD
Nephrology · Fairfax, VANPI 1225124779
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,809 of the $67,846 with a category attached, or 64.6%. Travere Therapeutics, Inc. accounts for 64.2% of it on its own, with 32 other manufacturers making up the rest. Among nephrology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $198.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$44K
- Vifor Pharma, Inc.$16K
- Kaneka Medical America LLC$3K
- Mallinckrodt Hospital Products Inc.$588
- AstraZeneca$416
- Amgen$396
- plus $4K from 27 others
Across 84 payments — averaging $6539.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$401K
- Akebia Therapeutics Inc$80K
- Vertex$46K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$23K
What the payments were for
- Consulting fees$10,72816%
- Speaking & faculty fees$43,80965%
- Travel & lodging$4,8257%
- Food & beverage$8,19012%
- Education$2930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 102 | $43,552 |
| Vifor Pharma, Inc. | 53 | $15,840 |
| Kaneka Medical America LLC | 2 | $3,348 |
| Mallinckrodt Hospital Products Inc. | 20 | $588 |
| AstraZeneca(2 entities) | 16 | $416 |
| Amgen(2 entities) | 17 | $396 |
| Otsuka America Pharmaceutical, Inc. | 13 | $373 |
| Calliditas Therapeutics US Inc. | 7 | $301 |
| Akebia Therapeutics Inc | 12 | $283 |
| OPKO Pharmaceuticals, LLC | 13 | $267 |
| Fresenius USA Marketing, Inc. | 13 | $261 |
| Mallinckrodt Enterprises LLC | 10 | $247 |
| ANI Pharmaceuticals, Inc. | 7 | $244 |
| GSK | 7 | $188 |
| Novartis | 9 | $185 |
| Bayer | 4 | $182 |
| Recor Medical Inc | 2 | $157 |
| Arbor Pharmaceuticals, Inc. | 6 | $149 |
| Teva Pharmaceuticals USA, Inc. | 1 | $139 |
| Aurinia Pharma U.S., Inc. | 2 | $121 |
| Johnson & Johnson | 1 | $104 |
| Novo Nordisk | 3 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Ardelyx, Inc. | 4 | $82 |
| Daiichi Sankyo Inc. | 4 | $71 |
| Shire North American Group Inc | 2 | $44 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Medtronic | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Filspari$14,339
- Veltassa$12,925
- LIPOSORBER$3,348
- PURIFIED CORTROPHIN GEL$143
- AJOVY$139
- Paradise Ultrasound Renal Denervation System$134
- TARPEYO$125
- Kerendia$114
- XARELTO$104
How this compares
$67,846 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 241 | $303,392 |
| JardianceEmpagliflozin | 221 | $268,381 |
| VeltassaPatiromer Calcium Sorbitex | 77 | $119,006 |
| EntrestoSacubitril/Valsartan | 25 | $33,894 |
| OzempicSemaglutide | 22 | $30,486 |
| Sevelamer Carbonate | 108 | $21,208 |
| EliquisApixaban | 18 | $13,833 |
| Valsartan | 161 | $7,003 |
| Potassium Citrate ErPotassium Citrate | 52 | $6,648 |
| Torsemide | 153 | $6,145 |
| Cinacalcet Hcl | 33 | $4,893 |
| Febuxostat | 17 | $4,728 |
| Calcitriol | 305 | $4,596 |
| Nebivolol Hcl | 49 | $4,195 |
| Midodrine Hcl | 36 | $3,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $416 | $303,392241 claims |
| NovartisEntresto | $185 | $33,89425 claims |
| Novo NordiskOzempic | $94 | $30,48622 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $244 | $7,003161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 298 nephrology providers in Virginia.
Other nephrology in Fairfax
- Reza ZonoziFairfax$262K
- Ali AssefiFairfax$64K
- Kinjal PatelFairfax$31K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Renu Regunathan-ShenkFairfax$6K
- Ranjit CheriyanFairfax$4K
- Ramon MendezWoodbridge$791K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.